Detalles de la búsqueda
1.
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves.
BMC Gastroenterol
; 23(1): 230, 2023 Jul 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37407913
2.
Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers.
Int J Mol Sci
; 24(3)2023 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36768710
3.
Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study.
Dig Dis
; 36(4): 264-268, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29669354
4.
New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Helicobacter
; 22(3)2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28125857
5.
Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.
J Clin Med
; 13(6)2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38541765
6.
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Expert Opin Biol Ther
; 24(1-2): 101-109, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38250818
7.
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Inflamm Bowel Dis
; 29(3): 376-383, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35579320
8.
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Expert Opin Biol Ther
; 23(3): 293-304, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36843568
9.
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Expert Opin Pharmacother
; 24(14): 1649-1656, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37358928
10.
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Biomedicines
; 10(8)2022 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35892698
11.
Barrett's esophagus: results from an Italian cohort with tight endoscopic surveillance.
Acta Biomed
; 93(1): e2022130, 2022 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35315405
12.
A non-invasive combined strategy to improve the appropriateness of upper gastrointestinal endoscopy.
Acta Biomed
; 93(4): e2022210, 2022 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36043968
13.
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Expert Opin Biol Ther
; 22(2): 313-320, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34904510
14.
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
J Gastrointestin Liver Dis
; 31(4): 411-416, 2022 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36535057
15.
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study.
Therap Adv Gastroenterol
; 14: 17562848211023384, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34249147
16.
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
Sci Rep
; 11(1): 10368, 2021 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33990652
17.
Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD.
J Gastrointestin Liver Dis
; 30(1): 25-29, 2021 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33548125
18.
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.
Therap Adv Gastroenterol
; 14: 17562848211031420, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34349836
19.
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Aliment Pharmacol Ther
; 54(11-12): 1432-1441, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34694009
20.
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
J Gastrointestin Liver Dis
; 30(4): 456-461, 2021 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34812437